CurrentCareSourcePolicy N/A

Spevigo (spesolimab-sbzo) — Coverage Criteria for Generalized Pustular Psoriasis (GPP)

Defines prior authorization medical policy for Spevigo (spesolimab-sbzo) as a medical benefit for treatment of acute flares of Generalized Pustular Psoriasis (GPP) in adults; applies to CareSource-covered members in Arkansas (PASSE).

Policy Summary

PayerCareSource

PolicySpevigo (spesolimab-sbzo) — Coverage Criteria for GPP

Policy CodePolicy N/A

Change TypeNo material change

Effective DateMar 1, 2024

Next Review DateN/A

Key ActionObtain prior authorization and document age, GPP diagnosis, GPPPGA total and pustulation subscores, presence of fresh pustules, and prescriber dermatology involvement.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

900 mgsingle IV dose allowed

3 weeksinitial approval duration

>=18min age

Effisayil-1pivotal trial

Coverage Criteria for Spevigo (spesolimab-sbzo)

inv-01: Initial Therapy — Covered when ALL of the following are met for initial authorization:

Covered when ALL of the following are met for initial authorization:

Initial Authorization Criteria: Member is at least 18 years of age

chunk 1

Diagnosis: Member has a diagnosis of Generalized Pustular Psoriasis (GPP)

chunk 1

Prescriber: Medication must be prescribed by or in consultation with a dermatologist

chunk 1

Acute flare severity:

Policy Summary

PayerCareSource

PolicySpevigo (spesolimab-sbzo) — Coverage Criteria for GPP

Policy CodePolicy N/A

Change TypeNo material change

Effective DateMar 1, 2024

Next Review DateN/A

Key ActionObtain prior authorization and document age, GPP diagnosis, GPPPGA total and pustulation subscores, presence of fresh pustules, and prescriber dermatology involvement.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Member has an acute flare of GPP of moderate to severe intensity defined by ALL of: presence of fresh pustules (new appearance or worsening of pustules); GPPPGA total score >= 3; GPPPGA pustulation subscore >= 2

Baseline exclusions: Member does NOT have any of the following: active tuberculosis infection; pustulation restricted to psoriatic plaques; at least 5% body surface area covered with erythema and presence of pustules

chunk 1

inv-02: Reauthorization — Reauthorization/Continuation criteria

Reauthorization/Continuation

Reauthorization: Medication will not be authorized for continuous use

chunk 2

CareSource considers Spevigo (spesolimab-sbzo) not medically necessary for the treatment of any conditions that are not specifically listed in this policy. Off-label uses or indications outside those described herein will not be covered; providers should refer to the plan's Off-Label policy for guidance on any non-listed indications.

Medication will not be authorized for continuous use. Requests for ongoing or maintenance therapy beyond the acute flare indication described in this policy are considered not medically necessary for non-listed indications and will be denied.

Initial Therapy Dosing and Administration

inv-15: Initial Therapy — Initial dosing and administration (single IV dose etc.)

Initial dosing and administration

Dose: Administer a single 900 mg (2 vials) IV infusion over 90 minutes; if flare symptoms persist, an additional 900 mg IV dose may be administered

chunk 1

Approval duration: If criteria are met, medication will be approved for 3 weeks

chunk 1

Continuation / Reauthorization Criteria

inv-16: Continuation Therapy — Reauthorization rules

Reauthorization rules

No continuous use: Medication will not be authorized for continuous use

chunk 2

Billing and Clinical Measure Codes

Billing CodesHCPCS

J3590

Unclassified biologics (billing code listed for Spevigo)

inv-06: GPPPGA total score — assessment threshold

Assessment thresholdGPPPGA total score ≥ 3

ContextRequired as part of defining a moderate-to-severe acute GPP flare for initial authorization

Age requirementMember must be at least 18 years of age when using this threshold

inv-07: GPPPGA pustulation subscore — assessment threshold

Assessment thresholdGPPPGA pustulation subscore ≥ 2

ContextRequired along with total GPPPGA ≥ 3 and presence of fresh pustules to define an eligible acute flare

UsePart of initial authorization criteria for Spevigo in GPP flares

Provider Actions and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for Spevigo (spesolimab-sbzo). Billing code J3590 applies and the benefit type is medical. Authorization is for acute flares per the policy criteria; medication will not be authorized for continuous use.

J3590 (Spevigo billed as unclassified biologic)
Benefit type: Medical
Authorization limited to acute GPP flares per documented criteria; not for continuous use

Step Therapy

No Step Therapy Specified

No step therapy requirements are specified for Spevigo in this policy.

No step therapy requirements

Documentation Required

Provider Documentation Requirements

Prescriptions must be written by or in consultation with a dermatologist. Provider documentation must include patient age, confirmed diagnosis of Generalized Pustular Psoriasis (GPP), documentation of an acute moderate-to-severe flare (including GPPPGA total score ≥3 and pustulation subscore ≥2), description of pustule presence/worsening and body surface area involvement, and any relevant exclusions (e.g., active tuberculosis).

Prescriber: dermatologist or in consultation with dermatologist
Document: patient age (≥18 years), diagnosis of GPP
Document: acute flare severity — GPPPGA total score ≥3 and pustulation subscore ≥2
Document: presence of fresh/worsening pustules and BSA involvement
Document: absence of exclusions (e.g., active tuberculosis)

Denial Risk

Denial / Limitation Notice

Denials or limitations may occur if the medication is requested for continuous use or for indications not listed in this policy; use for non‑listed conditions is considered not medically necessary.

Requests for ongoing/continuous therapy will be denied
Requests for indications outside those enumerated (GPP acute flares) are not medically necessary

Background

Spevigo (spesolimab-sbzo) is an interleukin-36 receptor antagonist approved for treatment of acute flares of Generalized Pustular Psoriasis (GPP). GPP is a rare neutrophilic skin disease characterized by widespread sterile pustules that can be severe or life-threatening. Regulatory approval and coverage in this policy are limited to the specified GPP acute-flare indication; other uses are not covered under this policy.

Definitions and Assessment Tools

inv-13: GPP — definition of Generalized Pustular Psoriasis

DefinitionGeneralized Pustular Psoriasis (GPP): a rare neutrophilic skin condition characterized by episodes of widespread sterile pustules; may occur with or without preceding plaque psoriasis

Clinical riskFlares can be life-threatening due to complications such as sepsis and multisystem organ failure

Clinical presentationEpisodes involve widespread eruptions of sterile pustules, often with high pustule density and impaired quality of life

inv-14: GPPPGA — definition and components of the Physician Global Assessment tool

DefinitionGeneralized Pustular Psoriasis Physician Global Assessment (GPPPGA): a physician-rated tool used to assess flare severity with a total score and a pustulation subscore

ComponentsTotal score (used to define overall severity) and pustulation subscore (assesses pustule burden)

Policy thresholdsPolicy requires GPPPGA total score ≥ 3 and pustulation subscore ≥ 2 to define a moderate-to-severe acute flare

Step Therapy Requirements

Step	Requirement
1	No step therapy specified in policy.

Quantity Limits and Dose Restrictions

inv-18: Spevigo (spesolimab-sbzo) — 900 mg single dose (2 vials); additional single 900 mg dose allowed if symptoms persist

Standard doseSingle 900 mg dose (2 vials) administered IV over 90 minutes

Repeat dosingIf flare symptoms persist, an additional single 900 mg IV dose may be administered

Quantity limit contextDose specified as the allowed/quantity limit for initial therapy

Site of Care and Administration

Billing Rule

Infusion center — IV infusion over 90 minutes (medical benefit)

Spevigo is administered as a single 900 mg IV infusion over 90 minutes (medical benefit); an additional 900 mg IV dose may be given if flare symptoms persist.

Administer 900 mg (2 vials) IV over 90 minutes
Additional single 900 mg IV dose allowed if symptoms persist